-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O7A2Y5ofilq3Ecs9llHk+o/IcaynuHA2C++8tliixEk9+0tb2V8PTT82F5doe1xR
 skbrOO4YiNlYlj6ozK/TbQ==

<SEC-DOCUMENT>0001188112-08-003424.txt : 20081222
<SEC-HEADER>0001188112-08-003424.hdr.sgml : 20081222
<ACCEPTANCE-DATETIME>20081222173024
ACCESSION NUMBER:		0001188112-08-003424
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20081216
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20081222
DATE AS OF CHANGE:		20081222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	RADIO & TV BROADCASTING & COMMUNICATIONS EQUIPMENT [3663]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		081264946

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t64262_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
  <head>
    <title>t64262_8-k.htm</title>
<!-- Licensed to: ga4252-->
<!-- Document Created using EDGARizer 4.0.6.3 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON,
D.C. 20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">______________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">FORM
8-K</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
REPORT</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT
TO SECTION 13 OR 15(d) OF THE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
of report (Date of earliest event reported): December 16, 2008</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Applied
DNA Sciences, Inc</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
Name of Registrant as Specified in Charter)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nevada</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State
      or Other Jurisdiction</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of
      Incorporation)</font></div>
              </td>
              <td valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">002-90539</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission
      File Number)</font></div>
              </td>
              <td valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">59-2262718</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS
      Employer</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification
      No.)</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25
Health Sciences Drive, Suite 113</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stony
Brook, New York 11790</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of Principal Executive Offices) (Zip Code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">631-444-
8090</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s
telephone number, including area code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not
Applicable</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
Name or Former Address, if Changed Since Last Report)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
              <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
              <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#160;</font></td>
              <td valign="top" width="95%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
            </tr>
            <tr>
              <td valign="top" width="5%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: wingdings">&#168;</font></div>
              </td>
              <td valign="top" width="95%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: gainsboro" noshade size="1">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
2.02 Results of Operations and Financial Condition.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
December 16, 2008, Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) announced by press
release its financial results for its fourth fiscal quarter and fiscal year
ended September 30, 2008.&#160;&#160;A copy of the press release is attached
hereto as Exhibit 99.1.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
information in Item 2.02 of this Current Report shall not be deemed &#8220;filed&#8221; for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that section.&#160;&#160;The
information in Item 2.02 of this Current Report shall not be incorporated by
reference into any registration statement or other document pursuant to the
Securities Act of 1933, except as shall be expressly set forth by specific
reference in such filing.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
5.02.&#160;&#160;Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">2005 Incentive Stock
Plan</font>.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June
17, 2008, the Board of Directors of the Company unanimously adopted an amendment
to the Company&#8217;s 2005 Incentive Stock Plan (the &#8220;2005 Plan&#8221;) <font style="DISPLAY: inline; COLOR: #000000">in order </font><font style="DISPLAY: inline; COLOR: #000000">to increase the number of shares of
common stock subject to the </font>Company&#8217;s 2005 Incentive Stock Plan <font style="DISPLAY: inline; COLOR: #000000">from 20 million to 100 million and
</font><font style="DISPLAY: inline; COLOR: #000000">to </font><font style="DISPLAY: inline; COLOR: #000000">limit to 25 million the number of shares
that can be covered by awards made to any participant in any calendar
year</font><font style="DISPLAY: inline; COLOR: #000000"> (the &#8220;Share Increase
Amendment&#8221;)</font><font style="DISPLAY: inline; COLOR: #000000">.</font>&#160;&#160;On December 16,
2008, the Company&#8217;s stockholders approved the <font style="DISPLAY: inline; COLOR: #000000">Share Increase Amendment</font> to the
2005 Plan at the Company&#8217;s 2008 Annual Meeting of Stockholders.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
following description of the 2005 Plan is qualified in its entirety by reference
to the full text of the 2005 Plan, as amended and restated in its entirety, a
copy of which will be filed as an exhibit to our quarterly report on Form 10-Q
for the quarter ending December 31, 2008.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Types
of Awards</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Awards
under the 2005 Plan may be in the form of options to purchase shares of our
common stock (including options intended to qualify as &#8220;incentive stock options&#8221;
(&#8220;ISOs&#8221;) within the meaning of Section 422 of the Internal Revenue Code of 1986,
as amended (the &#8220;Code&#8221;) and options which do not qualify as ISOs), restricted
stock awards, deferred stock awards and other forms of stock based
awards.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Authorized
Shares</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
to adjustment to reflect stock splits, stock dividends and other changes in
capitalization, an aggregate of 100 million shares of our common stock may be
issued under the 2005 Plan. For this purpose, shares subject to an award that is
forfeited, terminated or expired and shares repurchased pursuant to the 2005
Plan will remain available for issuance pursuant to the 2005 Plan.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Eligibility</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Awards
under the 2005 Plan may be granted to any of our directors, officers, employees
or consultants.&#160;&#160;<font style="DISPLAY: inline; COLOR: #000000">ISOs
may only be issued to our employees.&#160;&#160;</font>There are currently
approximately 13 employees eligible to be granted options under the 2005
Plan.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: gainsboro" noshade size="1">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Administration
of the 2005 Plan</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The 2005
Plan is administered by the Compensation Committee of our Board of
Directors.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Terms
and Conditions of Awards under the 2005 Plan</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subject
to the provisions of the 2005 Plan, the Compensation Committee, acting in its
discretion, has the responsibility and full power and authority to select the
persons to whom awards will be made, to prescribe the terms and conditions of
each award and make amendments thereto, to construe, interpret and apply the
provisions of the 2005 Plan and of any agreement or other instrument evidencing
an award and to make any and all determinations and take any and all other
actions as it deems necessary or desirable in order to carry out the 2005
Plan.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Stock options</font>. Stock options
shall have such vesting and other terms and conditions as the Compensation
Committee, acting in its discretion, may determine. The exercise price per share
of our common stock covered by an option may not be less than 100% of the fair
market value per share on the date of grant (110% of fair market value in the
case of ISOs granted to an employee who is a 10% stockholder within the meaning
of the Internal Revenue Code). The Compensation Committee, acting in its sole
discretion, may permit the exercise price to be paid in whole or in part in cash
or by check, by means of a broker assisted cashless exercise procedure, or in
the form of unrestricted shares of previously owned shares of our common stock.
Unless sooner terminated, an option shall automatically expire on the tenth
anniversary of the date it is granted (the fifth anniversary in the case of an
ISO granted to an employee who is a 10% stockholder). Unless the terms of an
option provide otherwise, the non-vested portion of an option will be forfeited
upon termination of a participant&#8217;s employment or other service, and the vested
portion will terminate if and to the extent it is not exercised within 90 days
after termination of employment (one year if the termination is due to death or
disability). However, if a participant&#8217;s employment or service is terminated for
&#8220;cause&#8221; (as defined in the 2005 Plan), the participant&#8217;s outstanding options
will terminate immediately, whether or not otherwise vested). If we are sold or
merge with another company, outstanding options may be converted into
economically equivalent options of the acquiring or successor company. If the
outstanding options are not so converted, then vesting of the options may be
accelerated and, in any event, the outstanding options that are not exercised
will terminate immediately before the sale or merger is completed.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Restricted Stock and other Stock
Awards</font>. In general, restricted stock is common stock that is subject to
transfer restrictions and forfeiture conditions as determined by the
Compensation Committee. Restricted stock awards may vest on the basis of the
satisfaction of performance conditions established by the Compensation Committee
or on the passage of time. The Compensation Committee may provide that
participants who receive restricted stock awards are entitled to vote their
shares of restricted stock and/or receive the dividends paid on the
shares.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
general, a deferred stock award is a right to receive one share of our common
stock or cash equal to the value of one share at the end of a specified period,
subject to such conditions as the Compensation Committee may determine. Deferred
stock awards may vest on the basis of the satisfaction of performance conditions
established by the Compensation Committee or on the passage of time. The holder
of a deferred stock award has no rights as a stockholder with respect to the
underlying shares unless and until the award vests and the award is settled in
shares.&#160;&#160;However, the Compensation Committee may provide for the
payment of dividend equivalents in the form of cash or shares in an amount equal
to the dividends that would have been payable if the shares were
outstanding.</font></div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify">&#160;</div>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: gainsboro" noshade size="1">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
            </div>
            <div>&#160;</div>
            <div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Amendment
and Termination</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Board
of Directors may terminate the 2005 Plan or amend it in any respect, except that
stockholder approval shall be required for any amendment that would (a) increase
the number of shares subject to the 2005 Plan, (b) decrease the price at which
awards may be granted, (c) materially increase the benefits to participants, or
(d) change the class of persons eligible to receive awards. However, participant
consent will be required with respect to an amendment that would alter or impair
the participant&#8217;s rights and obligations under any outstanding award. If not
sooner terminated, the 2005 Plan will expire on the tenth anniversary of the
date of its original adoption. Any awards outstanding at the time of such
termination or expiration will continue in accordance with their
terms.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Equity
Award Grants</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June
17, 2008, the Board of Directors of the Company granted nonstatutory stock
options under the 2005 Plan to certain key employees of the Company, including
our named executive officers (&#8220;NEOs&#8221;).</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Following
the stockholders&#8217; approval of the Share Increase Amendment to the 2005 Plan at
the Company&#8217;s 2008 Annual Meeting of Stockholders, t<font style="DISPLAY: inline; COLOR: #000000">he Company will enter into a</font><font style="DISPLAY: inline; COLOR: #000000">n Employee Nonstatutory Stock Option
</font><font style="DISPLAY: inline; COLOR: #000000">Agreement with each of the
following NEOs:</font></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div>
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Name</font></font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Award Type</font></font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Number of
      Awards</font></font></div>
                      </td>
                      <td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Exercise
    Price</font></font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Award
  Plan</font></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="13%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">James A.
      Hayward</font></font></div>
                      </td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Nonstatutory Stock
      Options</font></font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">17,000,000</font></font></div>
                      </td>
                      <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="11%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">$0.11</font></font></div>
                      </td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">2005 Incentive Stock
      Plan</font></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="13%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Kurt H.
    Jensen</font></font></div>
                      </td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Nonstatutory Stock
      Options</font></font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">5,000,000</font></font></div>
                      </td>
                      <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="11%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">$0.11</font></font></div>
                      </td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">2005 Incentive Stock
      Plan</font></font></div>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="13%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Ming-Hwa
    Liang</font></font></div>
                      </td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Nonstatutory Stock
      Options</font></font></div>
                      </td>
                      <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="14%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">7,000,000</font></font></div>
                      </td>
                      <td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="11%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">$0.11</font></font></div>
                      </td>
                      <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
                      <td valign="top" width="20%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">2005 Incentive Stock
      Plan</font></font></div>
                      </td>
                    </tr>
                </table>
              </div>
              <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
options granted to the NEOs vested with respect to 25% of the underlying shares
on the date of grant, and the remaining will vest ratably each anniversary
thereafter until fully vested on the third anniversary of the date of
grant.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
8.01.&#160;&#160;Other Events.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">2008
Annual Meeting of Stockholders</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
December 16, 2008, the Company&#8217;s 2008 Annual Meeting of Stockholders was held at
the Charles B. Wang Center, Stony Brook University, Stony Brook, New
York.&#160;&#160;On December 16, 2008, the Company issued a press release
announcing the results of its 2008 Annual Meeting of Stockholders.&#160;&#160;At
the 2008 Annual Meeting of Stockholders, the Company&#8217;s stockholders elected
three incumbent director nominees to the Company&#8217;s Board of Directors for one
year terms; approved the reincorporation of the Company from the State of Nevada
to the State of Delaware; approved an amendment to increase the number of shares
subject to the Company&#8217;s 2005 Incentive Stock Plan and limit the number of
shares that can be covered by awards made to any participant in any calendar
year; and ratified the selection of RBSM LLP as the Company&#8217;s independent
registered public accounting firm for the fiscal year ending September 30,
2008.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A copy of
the press release is attached hereto as Exhibit 99.2.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div id="FTR">
                    <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
                  </div>
                  <div id="PN" style="PAGE-BREAK-AFTER: always">
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
                    <div style="WIDTH: 100%; TEXT-ALIGN: center">
                      <hr style="COLOR: gainsboro" noshade size="1">
                    </div>
                  </div>
                  <div id="HDR">
                    <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
                  </div>
                </div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Change
of Domicile</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
December 17, 2008, the Company filed with the Nevada Secretary of State articles
of conversion and filed with the Delaware Secretary of State (i) a certificate
of conversion and (ii) a certificate of incorporation that will govern the
Company as a Delaware corporation.&#160;&#160;Upon the effectiveness of such
filings, instead of being subject to the corporate laws of Nevada, the Company
will be subject to the Delaware General Corporation Law.&#160;&#160;In addition,
the Board of Directors of the Company will adopt bylaws for the resulting
Delaware corporation.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
9.01 Financial Statements and Exhibits</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <div align="justify">
          <div align="justify">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(d)</font></div>
                  </td>
                  <td valign="top" width="85%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibits.</font></div>
                  </td>
                </tr>
                <tr>
                  <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="85%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                  <td align="left" valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      99.1</font></div>
                  </td>
                  <td align="left" valign="top" width="85%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                      <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
      release of Applied DNA Sciences, Inc., dated December 16,
      2008.</font></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="85%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="10%">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      99.2</font></div>
                  </td>
                  <td align="left" valign="top" width="85%">
                    <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
      release of Applied DNA Sciences, Inc., dated December 16,
      2008.</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: gainsboro" noshade size="1">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="center">
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Applied
      DNA Sciences, Inc.</font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="22%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
              </td>
              <td align="left" valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/ James A. Hayward</font></font></div>
              </td>
              <td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="22%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James
      A. Hayward</font></div>
              </td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td align="left" valign="top" width="22%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">Chief
      Executive Officer</font></div>
              </td>
              <td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
December 22, 2008</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: gainsboro" noshade size="1">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
INDEX</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <div align="left">
          <div align="left">
            <table cellpadding="0" cellspacing="0" width="100%">
                <tr>
                  <td align="left" valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      No.</font></div>
                  </td>
                  <td align="left" valign="top" width="90%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Description</font></div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="10%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      99.1</font></div>
                  </td>
                  <td align="left" valign="top" width="90%">
                    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                      <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
      release of Applied DNA Sciences, Inc., dated December 16,
      2008.</font></div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                  <td align="left" valign="top" width="90%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
                </tr>
                <tr>
                  <td align="left" valign="top" width="10%">
                    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit
      99.2</font></div>
                  </td>
                  <td align="left" valign="top" width="90%">
                    <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press
      release of Applied DNA Sciences, Inc., dated December 16,
      2008.</font></div>
                  </td>
                </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
    </div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title>ex99-1.htm</title>
<!-- Licensed to: ga4252-->
<!-- Document Created using EDGARizer 4.0.6.3 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="100%">
    </div>
    <div style="TEXT-ALIGN: right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 99.1</font></div>
    <div style="TEXT-ALIGN: left">&#160;</div>
    <div style="TEXT-ALIGN: center"><img src="img.jpg" alt="LOGO"><br></div>
    <div style="TEXT-ALIGN: left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Applied DNA Sciences Averages 35% Growth
Over Last Four Quarters</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Announces Fourth Quarter and Fiscal Year
End 2008 Results</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; COLOR: #000000">STONY BROOK, N.Y.,
December 16, 2008/Market Wire/ -- </font><font style="DISPLAY: inline; COLOR: #000000">Applied DNA Sciences, Inc. (OTC Bulletin
Board: APDN) announced today its revenues for </font><font style="DISPLAY: inline; COLOR: #000000">the 4th quarter </font><font style="DISPLAY: inline; COLOR: #000000">and fiscal year ending September 30,
2008.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4th
      Quarter Revenue is up 137% or $167,495 from a year earlier to
      $289,415</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fiscal
      2008 Revenue is up 616% or $751,090 from a year earlier to
      $873,010</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cost
      of sales for the year ended September 30, 2008 was $171,332, netting a
      gross profit of $701,678. Cost of sales for the year ended September 30,
      2007 was $23,073, netting a gross profit of
  $98,847.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">&#8220;This year, APDN broadened its
commercial scope, gained traction for its multiple product offerings, expanded
its customer base and increased its revenues in each quarter of fiscal 2008,
averaging 35% growth quarter-over-quarter for the year. This builds on our
strategy of diversified revenue sources with managed risk concentration and
shortened sales cycles,&#8221; stated Dr. James Hayward, President and
CEO.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Costs and Expenses:</font></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Selling,
      general and administrative expenses for the twelve months ended September
      30, 2008 decreased 65% to $4.3 million from $12.1 million in the same
      period in 2007. Included within the selling, general and administrative
      expenses for the years ended September 30, 2008 and 2007 were expenses
      relating to liquidation damage accrual, fund raising and consultant costs
      of $1.1 million and $7.9 million, respectively<font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total
      operating expenses decreased to $4.9 million from $12.6 million, or a
      decrease of $7.7 million, primarily due to the reduction in accrual for
      liquidation damages and less consulting costs for the year ended September
      30, 2008 as compared to September 30,
2007.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      net loss for fiscal 2008 decreased by $6,501,935 from a year earlier to
      $6,802,898 as a result of a combination of the factors described above and
      less impactful changes in R&amp;D costs, Depreciation and Amortization and
      Other Income/Expenses.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Key 2008 achievements
include:</font></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Four
      consecutive quarters of increased revenues, averaging 35% growth,
      quarter-over-quarter.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expansion
      of diversified product lines including SigNature&#174; DNA, BioMaterial&#8482;
      Genotyping and BioActive&#8482; Ingredients to enhance the Company&#8217;s ability to
      capture a dominant position in the DNA authentication
    market.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
      </div>
      <div>
      </div>
      <div>
      </div>
      <div>
      </div>
      <div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: gainsboro" noshade size="1">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
        <div>
        </div>
        <div>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 36pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expansion
      of SigNature DNA markers in Cash-In-Transit industry with newly developed,
      forensically formulated products like AzSure&#8482; Security
  Ink.</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 36pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Training
      of UK police and other law enforcement teams on the detection and
      authentication of SigNature DNA markers in stolen
  cash.</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 36pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Continued
      repeat orders of BioActive Ingredients that are being used by leading
      global brands in personal care.</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 36pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Auditable
      process and controls throughout the company to support
      authentication.</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%">
              <tr valign="top">
                <td align="right" style="WIDTH: 36pt">
                  <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
                </td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Expanded
      patent and trademark portfolios which will form the basis for added value
      through future licensing revenue
opportunities.</font></div>
                </td>
              </tr>
          </table>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">The Company has made significant inroads
with its central SigNature DNA platform that uses botanically derived genomic
DNA to mark and authenticate a range of security inks, packaging labels, and
event tickets. This year, APDN has been able to develop more market-ready
products, enabling faster price quotations and more concise product cycles which
will provide a foundation for continued growth in 2009.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">&#8220;Despite the challenges of today&#8217;s
economy, APDN continued to expand and grow in fiscal 2008. Our strategy remains
focused on long-term sustainable growth and although the economic realities may
impact us slightly in the short term, our long-term goals remain intact,&#8221; stated
Kurt Jensen, Chief Financial Officer.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">APDN in Textiles:</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">One of the key highlights of the year
for APDN was our launch into the world of textiles. In addition to marking
fabrics with our SigNature DNA, we authenticate natural fibers by genotyping,
analyzing the unique DNA content found naturally in these goods. Our newly
launched services for textiles include:</font></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cotton
      authentication by FiberTyping&#8482; and PimaTyping&#8482;. With FiberTyping,
      retailers or brand owners can verify that the garment that is labeled as
      Pima cotton does, in fact, contain Pima cotton. This test can be used to
      establish cotton provenance throughout the logistic chain and can be
      effectively used in commerce to ensure both fabric quality and brand
      integrity. Management believes this assay will have utility for
      governments wishing to enforce cotton trade
  agreements.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">
            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SigNature
      DNA marks to authenticate textiles at all points of the logistic chain. We
      expanded our collaborations to include Yorkshire Forward, the Textile
      Centre of Excellence and its consortium of companies throughout the
      Yorkshire region in the UK.</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Dr. Benjamin Liang, Chief Technology
Officer, commented, &#8220;Our FiberTyping test, which was developed to help the
cotton industry, is ready for commercial use. We believe that the experience we
bring to cotton will also be of great value to the wool industry. We are looking
forward to our business collaborations with Supima and the </font><font style="DISPLAY: inline; COLOR: #000000">Yorkshire</font><font style="DISPLAY: inline; COLOR: #000000"> companies in marking and authenticating
textile and apparel in the new year.&#8221;</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">&#8220;We are grateful for the strong support
of our customers, strategic partners, employees and investors this year. We have
made significant progress toward our goals and we believe our vision and
strategy will take us there,&#8221; continued Dr. Hayward.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: gainsboro" noshade size="1">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">About APDN</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Applied DNA Sciences markets and sells
DNA encrypted and embedded solutions that are forensically authenticated by
machine readable devices. These solutions can be easily integrated with a range
of inks, threads, varnishes, adhesives as well as thermal ribbon, inkjet and
laser ink. Applied DNA Sciences&#8217; products can help protect the brands and
intellectual property that can easily be eroded by counterfeiting, product
diversion and fraud.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">The statements made by APDN may be
forward-looking in nature and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements
describe APDN&#8217;s future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties, many of
which are beyond the control of APDN. Actual results could differ materially
from those projected due to our short operating history, limited financial
resources, limited market acceptance, market competition and various other
factors detailed from time to time in APDN&#8217;s SEC reports and filings, including
our Annual Report on Form 10-K, filed on January 15, 2008 and our subsequent
quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly
any forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of unanticipated
events.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">SOURCE Applied DNA Sciences,
Inc.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">INVESTOR CONTACT: Debbie Bailey,
631-444-8090, fax: 631-444-8848/</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">MEDIA CONTACT: Deanne Eagle,
212-554-5436 /FCMN Contact: info@adnas.com / /</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Web site: http://</font><font style="DISPLAY: inline; COLOR: #000000; TEXT-DECORATION: underline">www.ADNAS.com
</font><font style="DISPLAY: inline; COLOR: #000000">/</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title>ex99-2.htm</title>
<!-- Licensed to: ga4252-->
<!-- Document Created using EDGARizer 4.0.6.3 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="COLOR: black" align="left" noshade size="1" width="100%">
    </div>
    <div style="TEXT-ALIGN: right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 99.2</font></div>
    <div style="TEXT-ALIGN: left">&#160;</div>
    <div style="TEXT-ALIGN: center"><img src="img.jpg" alt="LOGO"></div>
    <div style="TEXT-ALIGN: left">&#160;</div>
    <div style="TEXT-ALIGN: left">
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Applied DNA Sciences Announces Results
of Stockholder&#8217;s Meeting</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; COLOR: #000000">STONY BROOK, N.Y.,
December 16, 2008/Market Wire/ -- </font><font style="DISPLAY: inline; COLOR: #000000">Applied DNA Sciences, Inc. (OTC Bulletin
Board: APDN) announced today the results of its Annual Meeting of Stockholders
which was held today.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">At the meeting, stockholders voted to
reelect the existing three members of the Board of Directors to serve for the
ensuing year and approved the reincorporation of the Company from the State of
</font><font style="DISPLAY: inline; COLOR: #000000">Nevada</font><font style="DISPLAY: inline; COLOR: #000000"> to the State of </font><font style="DISPLAY: inline; COLOR: #000000">Delaware</font><font style="DISPLAY: inline; COLOR: #000000">. Stockholders also approved an
amendment to the Company&#8217;s 2005 Incentive Stock Plan to increase the number of
shares of common stock from 20 million to 100 million and limit to 25 million
the number of shares that can be covered by awards made to any participant in
any calendar year and ratified the appointment of RBSM LLP as the Company&#8217;s
independent registered public accounting firm for the fiscal year ending
September 2008.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">About APDN</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">Applied DNA Sciences markets and sells
DNA encrypted and embedded solutions that are forensically authenticated by
machine readable devices. These solutions can be easily integrated with a range
of inks, threads, varnishes, adhesives as well as thermal ribbon, inkjet and
laser ink. Applied DNA Sciences&#8217; products can help protect the brands and
intellectual property that can easily be eroded by counterfeiting, product
diversion and fraud.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">The statements made by APDN may be
forward-looking in nature and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements
describe APDN&#8217;s future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties, many of
which are beyond the control of APDN. Actual results could differ materially
from those projected due to our short operating history, limited financial
resources, limited market acceptance, market competition and various other
factors detailed from time to time in APDN&#8217;s SEC reports and filings, including
our Annual Report on Form 10-K, filed on December 16, 2008 and our subsequent
quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly
any forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of unanticipated
events.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">SOURCE Applied DNA Sciences,
Inc.</font></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; COLOR: #000000">INVESTOR CONTACT: Debbie Bailey,
631-444-8090, fax: 631-444-8848/</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MEDIA
CONTACT: Deanne Eagle, 212-554-5436 /FCMN Contact: info@adnas.com / /Web site:
http://<font style="DISPLAY: inline; TEXT-DECORATION: underline">www.ADNAS.com
</font>/</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 img.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!Z`:8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBDS0`M%(6Q3#,BD!F`)[$T`244@;(S
M2T`%%9&J:_!IDHA,;2RXR54XP/>GZ5KEOJN]45HY$&2C>E`&I129H!S0`M%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!32>*=
M5'5I3!H][,GWHX'9?J%)HM?03=M3SCQKX]NA?/IVCW'EQQC$EQ'@EF[@'L/<
M5YY--+<2M+-(\LC<EW8DG\33.O4DGU/>BO?I48THV2/%J595'>1T6@^-=7T.
M6-?M#7%J.L$K$C'L>H_#\J]PL+Z#4;"&[MI`\4J[E/\`GO7S8?:O9?A?,TGA
M-D;I%<NB_3"G^IKCQU&*C[1+4ZL'5ES<C)/$VF73:D;F*%Y8Y%'*C.T@5#X?
M9+"_GDNV\ATA.U)/EW9^M:GBKQ=9^&K=0Z&:ZE!,<*G''J3V%<:GB.[\1P>?
M=)#'L<JJQ`\=.I)YKS_93Y.=K0[?:1YN1;EV75KV6Y-P;F16)SPQ`'L*]"L9
M7FL8)9!AWC5F'N1S7F/Z5V,?B>VAT>)RPDN0H4QCCGW-0:'2T5R-IXNE>[1+
MF&,1L0"4SE?\:ZZ@`HHHH`****`"BBB@`HHJ&ZN[:RA,UW<101+UDE<*H_$T
M`3453M-7TW4&9;+4+6Y9?O"&97(^N#2SZKI]K<+;W%];13M]V.2558_0$YH`
MMT5G1>(-&GN?LT6K6,EQG'E)<(6SZ8!S4]YJ=AIX4WM[;VP;[OG2A,_3/6@"
MU16:WB+1$N!;OK%@LQ.!&;E`WY9JCXPM8[WPEJ>^29&BMI)HWAE:-@RJ2#D$
M4`;^:6O,=!A_MOX'6=I>ZP;![R%D^V2R#(/FD\DD9R!CK7:>%K)--\,:=9+J
M']H+#"$%T#D28[CD\=NM`&U16<WB#1DN?L[:M8B?.WRC<)NSZ8SFM`,",@\4
M`+163?:QHCF73;G5K..60&-HOM2QR<\8'((-<9\([FYFB\1PSWES=);:H\,+
M3S-(0@&``22:`/1I)$BC9Y&5$4$LS'``'<FJ']OZ1VU2R_\``A/\:T"`P((!
M!XP:\\^']G;/J/B%'@C=4N0JAE!VC+^M:0@G&4GT,YS:DDNIWEO?6]T#]GN(
M9@.OEN&Q^5%S>06<?F7,\4*$X#2,%&?J:Y'Q?H$=E9MKNCJMG?6?[PM$-HD3
M^(,!P?\`ZWTJSJ%^NN_#>XOGC'[VS9RO8,.OZBA4TTI+9Z"]HTVFM3I;6^MK
MU&>VN(IT4X+1N&`/IQ3;K4;2RV_:KJ"#=G;YKA<X],FO.--W>`O$D,4LI.DZ
MH@;<1GRV]S[9_(^U=7XQABGTJSWHKC[=!C//!<`_F*N5)*:5]&3&HW%M[HZ-
M)`Z!U8,K#(8="*@&HVC7K62W,1NE7<T(8%@/<=NM3Y"KZ`5Y/=W,MAXHM/%[
M./L=Y=O$,#'[M?D!/KD`G\*FE3YVU_5QU:G(DSUO/-+3$=74,C!E89!'0T\G
M%9&P451NM9TNQE\J[U*SMY,9V2SJAQ]":MQS1RQK)'(KHW1E.0?H:`'T5GSZ
M]H]M<&WGU6QBG'6-[A%;\B<UB>/=+AU[PL^GOKD6DB9T99W<!6`.=OWAD'ZT
M`=715'2D2UT>RA^U_:1'`BBX)SYH"@;L]\]?QJ,>(-%-P+<:O8&8G`C%RF[/
MIC.:`-*BJ]W?V=A$);RZ@MXR<!II`@)],FJ<OB30H"@FUK3HRX!4/=(-P/0C
MGF@#4HIB2QRQK)'(K(PR&4Y!'UJI=ZUI5A(([S4K.VD(R$FG5"?P)H`O45'%
M<0W$*S0RI)$PR'1@5(]B*I7&O:/:3>3<ZK902_\`/.6=4;\B<T`:-0W$2SV\
MD+\K(I5OH1@U(DB.@=&#*1D$<@BJ,FN:1'<?9WU2R6;=M\MKA0V?3&<YH$SP
M37-&NM!U66RN5Y7YD8='4]"*SZ^A=;\/Z?XAMEAOX=ZH<HZMM9#[&N*N/A)$
M96-OJKI$>BO`&('U!'\J]:ECH<OOZ,\VI@YJ7N['EQ.*]X\%:2^C^%[6&0J9
M9<S.5.1EN1^F*XGQ%\-6T[2A=Z9-+<O"A,T3`;F]T`Z?2L71_'>K:+I#:=`L
M<B@_NGD&3'SSQW'^?:BL_K-/]T^HJ7^SSO416\:7LE_XMOR^?W<IA48Z!>,?
MH?SIN@RRV?VB64,MLB;G!&.>V/>K.B2/J=_=ZC=L)+IF!+8QR>^/P%:.L1K)
MI-QO/W5W`Y[BHJ5DK8>W9%TZ3=ZU^[,^X\30^21;Q.9",`OP!7I[Z7'JWANS
MEABBBN'ACD!"@9RHR#7B^CZ;+K&KVVGPG:\S8W?W1W/X"O<=7EN]&T%IM/,&
MVS@)*S(6R%48`PPQTK+%4:=/EC#<UP]6<[REL8=EX9OC=Q_:(Q'"K`L=P.1[
M8KN*YF77+^QU%K:Z@CN$6W20M;(P8,S,%&TD\?*!G/!.>G33T:^GOK-Y;F-(
MY4FDB*HQ(&UBO?Z5Q.$DKLZ5.+=C4%%("*7-(L****`"BBB@`KD_&]WX9@CT
MY/$*>?(MRLUE:H&:269>%VHOWN6[\=,UUE>>>//#VL2^*]!\4Z/9+J3Z:2DE
MDSA"5.?F4GC//Z+0!RGQ+U2\%YX>UI="N])NX[U42YF>,22+UV$(S''L:W?B
MK9V]UKW@F&XACD2755B<%>J%DROTJEX_TKQ=XTTZSGMO#YM$L+A95MIIT,TQ
M(Y(P=H`Z=<G/M3_B/=:G<R^!KD:>MOJ3:F&2TFE!"OE=JLPX[#)'K4C.D^(G
MAW3+GP!J7^A6Z-8VCRVS)&%,)0;AM(Z=,<5YWXCUB?Q#^S]97U\-]W%=)$97
M&2Q5BN[/J1C-=GK\_C3Q3ISZ!%X;&EPW0\J[OI[I)%C3/.Q5.6R/7U[=:R_B
MCHMKX=^#D.DV8(@MIX5W$<L<G<Q]R23^-.PCLX/#6DW_`($M]*>PM_LTMFI"
M>6,!BGWA_M9.<]:X#X9:Q=ZC\)_$5I=R22?8HITB=R3\AB)"Y]CG\ZZ!-9\;
M2^&;?3;'PJ$NWMUB6]:\0P*I4#S!_%G'."/SJ6R\(77@WX;7VC:5:OJNH7:R
M>9M98@SNNW.6/W5&..O%,9B6D:2_LV,'4,!8RD9&<'S&Y'O6=K&M7NB_L]Z+
M)8SR02W.R`R1MM95)<GGMG;C\:U[;1_$\'P6?PV?#TIU+#6HC^TQ8*,2WF9W
M8P,XQUS5_2_!-QKOPIM?#&OVDNGW-O\`*K!DD(*G*N,'!!!P1GU]J5@N5A;I
M/\/QX?B\#ZFT+VF%;%O@R%>),^9G.[G/6LFYUOQ/X,^"I354FAU9IS9PR2.'
M9$8$@Y!/0!@/PKI=&U7QKHFGII-]X5?4);9!%#>6MU&L<R@84L&Y7@#_``%:
MVK^&;KQAX/GTSQ%]GAN9CYD?V4$K;L/N\G[Q'.3QG/2F(K^"?".C6O@BPCDT
M^TF>]M(Y+MWB#&9F&X[B>3R:P_@S#';Q>*(84"1IJTBJJ]``,`?I5OP_?^,]
M"T:#0[KPHUY-9QK;P7D-VBQ2JO"LV>5&/8GVH^&6C:_H-WKT&L:7Y*75XUS'
M<I*K(Y)P0!G('<9%*P'HE<'\//\`D)^)/^OO_P!F>NXG>2.WE>*,RR*I*H"`
M6..!D\5YYX<@\3:#<ZC,WAYIS>R^9@7<:[.2<=3GK713UA)7[&%1^_'0Z_Q5
M,D/A35&DP`;611GU(('ZFN9TN)X?@_,K_P`5K,P'L68BKE[I>O>*XEMM4ACT
MRP5PSQ1RB627!Z$C@"M+Q#97*>%9M-TFP\YGB\A(@X4(N,9R3V%--1BH7ZW$
MUS2<[=!-=T&/Q%X82R9E27RU:*0C[K`?R/3\:X^RUU[G0(-&U!RNIV-_!&RM
MU9!(`/RZ?K7H>D&YDTNW-Y;&VG"!7B+AMI''4?G7*>*/"$UWXBL=9T^/=()X
M_M*`@`JI!W\^PY%52J1UA/U7K_P15(/24?F;?BW5?[+\/3&,%KFY_P!'@1>I
M=N!C^=<SK&+WP?\`V-!H&KAH8U$+M;``,O?[W&>?SK3UB+6;SQ9ISC1S-IEE
M)N#^<@W,1C?@G/R^E==SC."?05$9*FHZ7>^Y3C[1R[;',?#W51J7A>"(DF:T
M_</GT'W3^6!^%=6:\\\-V'B+2?$]W/\`V,8=.OILO'YR'RADX(P><9/'O[5Z
M#S[U-=14VX[,JBVX+F/%K37[GX?ZAKMOXJ\/7<]GJ%[(YU6)0XD1^`I/3&!T
MSD9QBM/Q/XBTC0O@_P"?X,E*6<TOV6WEA9@8BQ)<Y;Y@>&Z]"16Q%?>*TTB\
MTG6O#4VLW;O(B3JT"V\T9)V[LL"HQU^7-1Z3\,8H?AI+X5U*Y\R6>0SO/&N1
M'(2"-N>H&`/4\]*R-C7\*^&+&#X?6^GJB*;ZS5KJ95!:5W3YF)/WCD\9]JY/
MQWX<'AGX'3Z2U[)>_9I(MLTBX/,HX`R<``XK7T&^\8>&=.BT.]\,RZFEF@AM
MKVTN(PLJ#A=P<@K@8'?I2>/M.\4>(?AZ^G)I,<NHW<J%XK>=0L"*P;EG(W'C
M''K2L(P?'.JW>G?!WPU;6<DL;7\=I;R-$<$H8LE0??&/IFM36+&&^\'S:!;>
M`-1AB6%A:C;;@12X.U\^;G.<$GJ?>KMSX1NO%/PQT_1=3MWTS4+2*,1Y<2>7
M+&-H;*GH1G\#[4[3O$/CFSLQ9ZGX1>[OHQL%S;W<2Q3?[1R<K[_RHL,R-:MM
M3B^`$\&O0NNHP6P602L'8%9<*<C/.W'-;OP^\/Z1)\-=,C?3;5TN[16N-T0)
ME)')8]Z3QM9>(]4^'MQID>GQ7NJ7N$D2VD$<<(W;NKD9P`!GOUP*O^#H=5TC
MX?6-M>:7(FH6=L4-H)$)<KG`#`XYX[\9I@>??#;7IM"^&'B:\4M-_9US)]G1
MSD*2J@#_`'<\_G75?"33XI?!D6N7&)M3U-Y)+FY?EWP[*`3Z8'3IS67\,_"V
ML:=I&MZ-XCT-H;6_D,FXS(ZL&`5E^5B0>^:M^'K7Q/\`#^)M"BT676M&5V>U
MNK>5$D0,<E&5B.Y)STY_`*PA-7TF?X=?#WQ/=6&HSS-/*9805VBW\QPN%&<<
M;LY`'TJEX'F$?@2VMY?!^I:@M]&9+NY`@873,22Q+2;CZ<BNR:PO_%?AV_L?
M$%C'80WBE(X(Y?,EC'8LP^7=D`X%<YX>_P"$N\$V@T&30)-:T^W)%G>VTZ(Q
M0DD*RL>",]?YTQD/PXT;Q1IOA76](O8YK%B7&F-,ZL8@RD#&TG&#@_C7-:-X
MDTOP]X;B\%^._#MU:0L["6X*'RYCOW!R5P>O=<]*].7_`(2S4-`OW86FE:E*
MF+.-?WWD>[L>&)]A@>]<YK`\1>*/"J^'[WPK+_:$J+'->7,D/DQ-C!F7:Q)(
MY(``]*`1Z%8S6]Q90S6KJ]NZ@QLAR"N.,&K%9OA_28]"T&RTN*1I$M8EC#MU
M;`ZUI&@1A>+]5;1O#-W=QMMFV[(O]\\`_AU_"O`2S,2S'+$DY->Q?%*.1_"\
M13)5+E2V/3!'\R*\='2O6P$5[-OS/+QDGSV)[6\GLI?,@<J3P>X(]ZL7NKW=
M]%Y4C*L?=5&,_6J%%=CIP<N=K4YE4DH\J>A):W$UE=17-NY2:)@Z,.H(KZ$M
MGM]?T")Y%W07<`WKDCAAR.*^=^M>F^$_'ND:5X?M+"]-RLL08,XC!7EB1WST
MKCQM)R2E%:G3A*BBVI/1G>77V#3&EU2Y=(0(EC>1V.-H)('YL?>N*?XEZ-I[
MR1:?87$T9D9V<MM!9B22,Y/4FN8\<^*_[?OQ!9SL=-C"E5VE=[XY)!].E<EU
M[U-#!IQO4*K8IJ5J9['I7Q,T>^G$-S'+9$]'D(*?B1T_&NSBE29%DC961AE6
M4Y!'L:^::]5^%^N274$VDW$N]H`'@R>0G((_#C\ZRQ.#C"//`TP^)<I<LST:
MBBBN`[@HHHH`****``\BN1\5^#;OQ+JFE7D>KI9KILPN(4%KYFYP0<L2PR.!
MQCUKKJ*`&1AQ$HD*E]HW%1@$^PKF?'/A"7QGHR:7_:(LH/,$DA$'F,Q'0`[A
M@5U-%`%+2K.:PTJUM)YUGDAC$9E5-F['`.,G''O5VBB@`HHHH`****`"BBB@
M!C$`$G@5S^H^)K5-*%WIT\%P?/CC()[&0(3CK6_(BNC(ZAE8$$-R"*\P@FTU
MO";:8D*B_@NU%ROD$''VCH3CGC%:TH1D]>Z,JDFM$>E0W4$^X0S1R;3AMC!L
M?7%+%=6\[.L,\<A0X<(P.T^^.E<CJ-BT6O:I;Z9"L,DNC,%6)0N7WD#IWYJA
MH<^FWFN:6;.YV7%LI1X+?3WBX*])6+$<8]^:7LURWN'M'>UCT`RQK(J,ZAWS
MM4GDXZXK+UK5FT^UCE@$<CFZB@=2<[0S`'IT.#5'Q'=Q:;JFC:I=$I:6[RI+
M(`2$+)A<@<]16'<W4=];W]Q"'\N36;5E+*02-L>#@]CBG"FFTWL*<VKI'8MJ
MUFSW$4%Q#)<0Y#1>8`<A<X_STIUOJ4)LH9KJ2&!WB61T,JD+D>O0C/&:Y7SM
M+LM:U_3WACCOI0TMOMA_@,`R0P''(/>FZ%:07FIZ4MU!%,JZ'$0)$#`'(!_&
MCV2M>_\`5@51WL=G]MM3)&GGQ;Y!F-=XRX]1ZTIO;47(MC<1"<\B,N-Q_#K7
M#/86EOX*GGBMHTFAO&\N0)\R!;G`P>H&,"LOQ#JEF9+U$M8+2>UOT9CY+&:3
MYAF3>.B\].?PIJDF[)B=9J-VCTB+5K":[DM([J)KB-MK1AAD'&<>]31WEM+*
M\4<\;R)]Y%<$K]1VKBQ+8+K>MV4,2QZE>+YEDPA()!@'(;''(;//?WK/T&>P
MFO-(MXIA#?VK?O((M/='^Z0PD?<1M[YH]FK7N-57>UCT9[B.,J'8*6.T9.,G
MTJ(ZC9BW^T&YA$'_`#U+C;^>:P?%=NEQ+HD,B[HVU%`PQP1M;]*R_$4%IHVL
M6-R\5O:Z8(I%)-H98DE)!R54CDCO4Q@FEKN.51J^AVDEY;1PB>2>-82,B1F`
M7\ZS-2UEK2]TF*W\N2*]G,;-G/R[2<CGVKE([W3;+2;:0+%<VMQ>2F.XN;1E
MAA!`.%C.203P.G>J>BRJSZ-;KNS!J\P*^6R!05)`P>GT[5<:2O=LB55O0[U-
M;MX;>"2_DBM6GD>.-3*&!P2/O#CH,^W2KT-W;SQF2*9)$7JRL"!^(KSZ=K.T
MT?1+Z_C5K2#4+@3LT6_"EY,9&#QG%6-27.IQ6.D[5M/$,*E]HV^2%`W.%[93
MCZ@4G25[)C55[M'>+*DD:O&P96&00<@BJ%_JL$-C?26T\,EQ;0O(8PX)!`SR
M!R*CUFSN?^$;N;32_DN!#LA`.,8&,#TXKF;6]T&70KZST^`1:A#I\@F0V^QU
MPN&#-CDY]SFHC!/4N<VM#K]/U&&\MXB)8FG,2O(B,"5R`>F<CK4POK5KAK=;
MB(SKUC#C</PKCI;2.VN/##6,4<$\D<BET4`M^Y)&3WYQUK&TV2T5[#3;N=(]
M7@N%+HE@YG+AN<R;L$$9R?2K]DG=ID.K)65CTJ2]M894BEGC21_NHS`%OH.]
M9^E:N;NWOI;HQQ+;WDMN#G`PK8&<]ZY/3KK2=*N[JW\06Q_M.:Z:1'FMS)YB
MD_(4;!X_'BH8TFM[B?4;M3-I%OJMPTT*J25;?Q(1_$!D<?C3]DK/47M7HSTE
M3D4IZ5'"Z21!XV#(W((.<BI#TK`Z#,U[2UUK1+JP8A3*GRL?X6!R#^8%?/=S
M;S6=S);7$;1S1-M96Z@U]*-7BGQ"U.WU/Q,8;6%";<>4TBCYI&SR/H.E=^`G
M)-QZ'#C8)Q4NIR5%=@WPT\0B-&1;9]R@X$N"/8Y%6;'X7:O-,OVR>WMHOXBK
M;V_`#C]:[_K-)*_,<:P]1NUCD]'TR?6=4@L;=26D;D@?='<GZ5Z4_P`*--(_
M=ZA=H<=2%/\`2NH\/>&['P[9>1:J6=N9)F`W.?\`#VK:`Q7FU\9*4O<=D=U'
M"QC'W]6?.NN:6VBZU=:<Q)\EL*Q&-RGD'\C5"O8?'7@Q]=(O[`C[=&@4QG`$
MBCW]:\CNK:XLKAX+F%XI4.&5U((KT</6C5BM=3BKT73EY$5=S\*[:63Q+-<*
M#Y<4!#$>I(P/T/Y5R>E:/?ZU>"VL8#*YY)Z!1ZD],5[7X/\`#:>&]*$#,'N9
M3OG<=,XZ#V'^-98NM&,'%/5FF%I.4U)[(Z.BBBO'/5"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`*3:O/`Y]J6B@`P/2DVCG@<TM%`"8![48'H*
M6B@!-H]!2X'I110`F!Z48'H*6B@!-HSG`SZT;1G.!^5+10`F!Z"C`/84M%`"
M;1C&!1@>@I:*`$*@CH*S8=*\O6+G4I9/-ED58XAMP(D'4#ZGDUITF*=Q-(*-
MHR3@<T8I:0Q,#T%&!G.!2T4`)@$YP*,#T%+10`UB$&20`!7&:Q\2-'TZ22&W
M$EY,C;3Y>`F?]X_T!J#XFZ[/INFP6-M(4DN]WF$=0@P"/QS^E>/@=,5WX7"*
MI'GGL<6(Q+A+E@>E7/Q5\_3[F.+3G@N60B)Q*&`/J>!6-\/M";5_$(OKB-GM
MK8F1F;HTG51[G/)KCZZKP#KLFE>(H+9I&^RW;")T[;CPK?F<?B:ZIT%2I2]G
MNSFA6<ZD?:'N`ZTM(.M+7C'K!BBBB@`J*6V@GQYT,<F.F]0:EHH`9'#%$NV.
M-47T4`"GX'I110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110!Y3\6[:1;[3KK!\MHVC^A!S_(_I7G0Z5]!^(]!MO$.FM9W`P1\T<@Z
MHW8UXEK'AO5-#F=;RUD$2L0LZKE']P?\:]?!UHN'(WJCS,72:GSK9F36EX=M
MI+KQ+IL,8)8W"'CL`P)/Y"J=M:7-[.(;6"2:4]$C0DUZQX%\%/H^W4[]<7S*
M0L61^Z!_J16V(K1IP=]S&C2<Y*QW@ZTM(*6O"/9"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
9**`"BBB@`HHHH`****`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
